BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 30, 2012
 |  BioCentury  |  Emerging Company Profile

Vascular Magnetics: A long-term force

Vascular Magnetics developing magnetically delivered paclitaxel for PAD

Drug-eluting stents were developed to better reduce restenosis compared with bare-metal stents following procedures like angioplasty, but for many patients neither of these interventions is effective long term. Vascular Magnetics Inc. is developing drug-loaded magnetic particles to reduce restenosis rates by delivering higher doses of anti-restenotic drugs than drug-eluting stents.

PAD is treated with angioplasty followed by a bare-metal or drug-eluting stent. According to co-founder, President and COO Richard Woodward, 20-40% of arteries become re-obstructed each year.

"There is some evidence that drug-eluting stents do not deliver an effective dose of the drug," Woodward said.

The company's Vascular Magnetics Intervention (VMI) system is designed to improve on the dosing problem by delivering higher doses of controlled-release anti-restenotic drugs to the arterial wall using a catheter and an external magnet.

A catheter filled with biodegradable, magnetic, drug-loaded particles is inserted along the same guidewire used...

Read the full 705 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >